Dopavision Appoints Mark S. Wuttke, Ph.D., as Chief Executive Officer

– Former Novartis ophthalmology program head significantly strengthens Dopavision’s management capabilities – Company recently initiated clinical trial of novel digital therapeutic for childhood myopia Berlin, Germany, May 25, 2022 — Dopavision, a company pioneering the development of digital therapeutics, today announced that Mark S. Wuttke, Ph.D., has been appointed as the Company’s Chief Executive Officer. […]

FAQs

FREQUENTLY ASKED QUESTIONS Technical FAQs Trial FAQs Return to Portal Home Technical FAQs Download all FAQs as a PDF This section provides guidance on how to respond to some common technical concerns with which caregivers may reach out to you. If you do not feel confident helping a caregiver with a technical question, please assure […]

Report a Technical Issue

REPORT A TECHNICAL ISSUE Technical Issue Form Return to Portal Home We encourage you to use this form to report technical issues you or participants may be experiencing. The information provided in this form goes directly to our Product team at Dopavision. One of our technical experts will review the report and get in touch […]

Tips

Tips How to Navigate Technical Issues How to Report Technical Issues Return to Portal Home Navigating Technical Issues Download as a PDF Dopavision does its best to ensure that the MyopiaX and content apps have no technical issues. Yet, unforeseen technical issues may still occur during the MyopiaX-1 clinical trial. If a participant’s caregiver reports […]

Guides

GUIDES Weekly Low Adherence Calls Return to Portal Home Purpose: Understand why children have not been performing the recommended number of treatment sessions over the past week. Download as a PDF Goal: Motivate participating children and their caregivers to resume the twice daily treatment sessions as soon as possible by: Building rapport… inquire about how […]

Ensaio clínico

ENSAIO CLÍNICO DE QUE TRATA O ENSAIO CLÍNICO MYOPIAX®? A finalidade deste ensaio é investigar a eficácia de MyopiaX® MyopiaX® é uma aplicação para smartphone destinada a abrandar o avanço da miopia em crianças e adolescentes. Estamos a levar a cabo um ensaio clínico (NCT04967287) para investigar a segurança e a eficácia de MyopiaX® para controlar o […]

Klinisch onderzoek

KLINISCH ONDERZOEK WAAR GAAT HET KLINISCH MYOPIAX®-ONDERZOEK OVER? Het doel van dit onderzoek is het bestuderen van de werkzaamheid van MyopiaX® MyopiaX® is een smartphone-applicatie waarmee een behandeling wordt gegeven om de progressie van myopie bij kinderen en adolescenten te vertragen. We voeren een klinisch onderzoek uit (NCT04967287) naar de veiligheid en werkzaamheid van MyopiaX® om de […]

Klinische Studie

KLINISCHE STUDIE WORUM GEHT ES BEI DER KLINISCHEN MYOPIAX®-STUDIE? In dieser Studie soll die Wirksamkeit von MyopiaX® untersucht werden MyopiaX® ist eine Smartphone-Anwendung, die eine Behandlung zur Verlangsamung des Fortschreitens der Myopie bei Kindern und Jugendlichen bietet. Wir führen eine klinische Studie (NCT04967287) durch, um die Sicherheit und Wirksamkeit von MyopiaX® zur Kontrolle des Fortschreitens der Myopie […]

Ensayo clínico

ENSAYO CLÍNICO ¿EN QUÉ CONSISTE EL ENSAYO CLÍNICO MyopiaX®? El objetivo de este ensayo es investigar la eficacia de MyopiaX® MyopiaX® es una aplicación para smartphone que proporciona un tratamiento para ralentizar la progresión de la miopía en niños y adolescentes. Estamos llevando a cabo un ensayo clínico (NCT04967287) para investigar la seguridad y eficacia de MyopiaX® para […]

The importance of treatment compliance

Compliance is an important aspect of myopia control that has not been well-studied or documented. In general, compliance refers to a patient’s adherence to the treatment regimen, but also includes completion of care procedures and attendance at follow-up visits.1 Compliance can be hard to measure, and reports are often subjective. As a result, compliance information […]